Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 1003-1008

  Giaisi, Marco ^a   Köhler, Rebecca ^a   Fulda, Simone ^b   Krammer, Peter H ^a   Li Weber, Min ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

anti cancer drug; apoptosis; c FLIP; Hodgkin's lymphoma; TRAIL; XIAP

Indexed keywords

CASPASE 8 INHIBITOR; HERBACEOUS AGENT; ROCAGLAMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENTIATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; PROTEINASE INHIBITION;

APOPTOSIS; BENZOFURANS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84862567754     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26458     Document Type: Article

References (25)

1. Re D, Thomas RK, Behringer K, Diehl V,. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005; 105: 4553-60. (Pubitemid 40807270)
2. Böll B, Borchmann P, Diehl V,. Emerging drugs for Hodgkin's lymphoma. Exp Opin Emerg Drugs 2010; 15: 585-95.
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63. (Pubitemid 29068521)
4. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-5.
5. Johnstone RW, Frew AJ, Smyth MJ,. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-98.
6. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, Jundt F, Hirsch B, Jöhrens-Leder K, Vornlocher HP, Bommert K, Stein H, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199: 1041-52. (Pubitemid 38619901)
7. Krammer PH, Arnold R, Lavrik I, Life and death in peripheral T cells. Nat Rev Immunol 2007; 7: 532-42. (Pubitemid 46987784)
8. Salvesen GS, Duckett CS,. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10. (Pubitemid 34685698)
9. Fulda S,. Cell death in hematological tumors. Apoptosis 2009; 14: 409-23.
10. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M, Jurgensmeier JM,. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198: 341-7. (Pubitemid 36987859)
11. Bleumink M, Köhler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M,. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2011; 18: 362-70.
12. Fulda S, Wick W, Weller M, Debatin KM,. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-15.
13. Fakler M, Loder S, Vogler M, Schneider K, Jeremias I, Debatin KM, Fulda S,. Small molecule XIAP inhibitors co-operate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009; 113: 1710-22.
14. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, Simmet T, Debatin KM, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425-34.
15. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG,. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-75.
16. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-26. (Pubitemid 39096830)
17. Akyurek N, Ren Y, Rassidakis GZ, Schlette EJ, Medeiros LJ,. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006; 107: 1844-51. (Pubitemid 44582954)
18. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamäki T, Johnson MS, Sistonen L, Eriksson JE,. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 2005; 280: 27345-55. (Pubitemid 41040776)
19. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M,. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601-13. (Pubitemid 43199444)
20. Wang W, Prince CZ, Mou Y, Pollman MJ,. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem 2002; 277: 21723-9. (Pubitemid 34952323)
21. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A, Younes A,. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-27. (Pubitemid 36917799)
22. Dutton A, O'Neil JD, Milner AE, Reynolds GM, Starczynski J, Crocker J, Young LS, Murray PG,. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 2004; 101: 6611-6. (Pubitemid 38586022)
23. Haag C, Stadel D, Zhou S, Bachem MG, Möller P, Debatin KM, Fulda S,. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011; 60: 225-37.
24. Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH, Li-Weber M,. The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int J Cancer 2007; 121: 1839-46. (Pubitemid 47417305)
25. Zhu JY, Giaisi M, Köhler R, Müller WW, Mühleisen A, Proksch P, Krammer PH, Li-Weber M,. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ 2009; 16: 1289-99.